Research Nester published a report titled “Cell Line Development Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of the global cell line development market in terms of market segmentation by product, cell type, application, industry, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global cell line development market is anticipated to grow with a CAGR of 12.39% over the forecast period, i.e., 2022-2031. The market is segmented by cell type into CHO cells, BHK 21 cells, NSO cells, murine C127 cells, NIH3T3 cells, L929 cells, and other cells, amongst these segments, BHK 21 cells segment is anticipated to garner the revenue of USD 2,455.4 Million by the end of 2031. Further, in the year 2021, the segment generated a revenue of USD 737.8 Million. Additionally, the CHO cells segment is expected to generate the largest revenue of USD 5,396.4 Million by the end of 2031.

The global cell line development market is estimated to garner a revenue of USD 14,679.1 Million by the end of 2031, up from a revenue of USD 4,588.5 Million in the year 2021. Growing risk of coronavirus, increasing risk of cancer-causing disease, and growing nervous system disorder cases are some of the major factors expected to boost the market growth during the forecast period.

Geographically, the global cell line development market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Out of which, the market in Asia Pacific is expected to garner the revenue of USD 3,945.1 Million by the end of 2031. In 2021 the market in Asia Pacific generated a revenue of USD 1,166.9 Million. Moreover, the market in North America is expected to hold the largest revenue of USD 5,086.7 Million by the end of 2031.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Rising Burden of Osteoporosis to Drive Market Growth

The International Osteoporosis Foundation estimates that osteoporosis results in more than 8.9 million fractures annually, with one occurring every three seconds.

In order to treat increasing osteoporosis cases, monoclonal antibodies are created, which are known to stimulate antibodies in patients. Therefore, as a result of this, the market is anticipated to grow throughout the forecast period.

However, inability to produce or develop a stable and authentic cell, low transfection efficiency, and integration frequency which are expected to operate as key restraint to the growth of global cell line development market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global cell line development market which includes company profiling of Lonza Group Ltd., Thermo Fisher Scientific, Corning Incorporated, General Electric Company, Sartorius AG, Selexis SA, Merck KGaA, WuXi AppTec, and others. The market research report also covers an in-depth analysis of the academia organizations who are associated with cell line development, the profiling of which includes organizations such as American Type Culture Collection (ATCC), and European Collection of Authentic Cell Cultures. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global cell line development market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.